CASI Pharmaceuticals (CASIF) Construction in Progress (2021 - 2023)

CASI Pharmaceuticals has reported Construction in Progress for 3 years, with the latest figure at $23000.0 in Q4 2023.

• For the quarter ending Q4 2023, Construction in Progress fell 99.6% year-over-year to $23000.0; the trailing twelve-month figure through Dec 2023 stood at $23000.0 (down 99.6% YoY), and the FY2023 full-year result was $23000.0, down 99.6% from the prior year.
• Construction in Progress for Q4 2023 stood at $23000.0, down from $5.7 million in the prior quarter.
• The five-year high for Construction in Progress was $12.1 million in Q4 2021, with the low at $23000.0 in Q4 2023.
• Historically, Construction in Progress has averaged $5.9 million across 3 years, with a median of $5.7 million in 2022.
• Annual changes were most pronounced in 2022 — Construction in Progress plunged 52.64% — and 2023, when it slumped 99.6%.
• CASI Pharmaceuticals' Construction in Progress stood at $12.1 million in 2021, then sank by 52.64% to $5.7 million in 2022, then tumbled by 99.6% to $23000.0 in 2023.
• The last three Construction in Progress figures came in at $23000.0 (Q4 2023), $5.7 million (Q4 2022), and $12.1 million (Q4 2021), per Business Quant data.